| Filed On | Filing |
|---|---|
| 05 Nov 2026 |
8-K: Notice of Delisting or Failure to Satisfy a Listing Rule
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. |
| 03 Nov 2026 |
8-K: Entry into a Material Definitive Agreement; Bankruptcy or Receivership +4 more
Certain portions of this exhibit have been omitted pursuant to Item 601 of Regulation S-K. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”. |
| 02 Nov 2026 |
8-K: Regulation FD Disclosure
– The Company Remains Focused on Supporting Patients and Advancing its Programs in Multiple Myeloma and Myelofibrosis – |
| 22 Oct 2026 |
8-K: Other Events
As previously disclosed in the Current Reports on Form 8-K filed by Karyopharm Therapeutics Inc. (the “Company”) on September 11, 2026 and October 14, 2026, the Company entered into a Forbearance Agreement and Limited Waiver to Indenture... |
| 14 Oct 2026 |
8-K: Other Events
As previously disclosed in the Current Report on Form 8-K filed by Karyopharm Therapeutics Inc. (the “Company”) on September 11, 2026, the Company entered into a Forbearance Agreement and Limited Waiver to Indentures, dated September 10,... |
| 18 Sep 2026 |
8-K: Material Modification to Rights of Security Holders; Amendments to Articles/Bylaws; Change in Fiscal Year
On September 17, 2026, the Pricing Committee of the Board of Directors of Karyopharm Therapeutics Inc., a Delaware corporation (the “Company”), acting pursuant to authority delegated to it by the Board of Directors on September 10, 2026 ... |
| 11 Sep 2026 |
8-K: Entry into a Material Definitive Agreement; Triggering Events That Accelerate a Financial Obligation +2 more
This Forbearance Agreement and Limited Waiver to Indentures, dated as of September 10, 2026 (this “Agreement”), is entered into by and among (i) Karyopharm Therapeutics Inc., a Delaware corporation (the “Company”) and each of the undersi... |
| 31 Aug 2026 |
8-K: Other Events
On August 31, 2026, Karyopharm Therapeutics Inc. (the “Company”) announced that it has submitted a supplemental New Drug Application (“sNDA”) to the U.S. Food and Drug Administration (“FDA”) seeking Accelerated Approval for XPOVIO® (seli... |
| 13 Aug 2026 |
8-K: Results of Operations and Financial Condition
Karyopharm Reports Second Quarter 2026 Financial Results and Highlights Continued Progress Toward Myelofibrosis sNDA Submission |
| 31 Jul 2026 |
8-K: Other Events
On July 30, 2026, Karyopharm Therapeutics Inc. (the “Company”) announced topline results from its Phase 3 XPORT-EC-042 trial evaluating selinexor as a maintenance-only therapy compared to placebo in adult patients with TP53 wild-type adv... |
| 17 Jul 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 28 May 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 14 May 2026 |
8-K: Results of Operations and Financial Condition
– Completed Enrollment of Phase 3 XPORT-EC-042 Trial in Endometrial Cancer; Topline Data Expected Mid-2026 – |
| 27 Mar 2026 |
8-K: Other Events
On March 24, 2026, Karyopharm Therapeutics Inc. (the “Company”) entered into a Securities Purchase Agreement with RA Capital Management (the “Investor”), pursuant to which the Company agreed to issue and sell (i) 1,030,354 shares of its ... |
| 24 Mar 2026 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +2 more
This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of March 24, 2026, by and among Karyopharm Therapeutics Inc., a Delaware corporation (the “Company”), and the purchaser listed on Exhibit A attached to this Agreement (the... |
| 03 Mar 2026 |
8-K: Entry into a Material Definitive Agreement; Other Events
SECOND AMENDMENT TO CREDIT AND GUARANTY AGREEMENT, dated as of February 27, 2026 (this “Amendment”), made by and among Karyopharm Therapeutics Inc., a Delaware corporation (“Company”) as borrower, the Lenders party hereto from time to ti... |
| 19 Feb 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On February 18, 2026, Karyopharm Therapeutics Inc. (the “Company”) held a Special Meeting of Stockholders (the “Special Meeting”). The following is a summary of the matters voted on at the Special Meeting. |
| 12 Feb 2026 |
8-K: Results of Operations and Financial Condition
– Top-Line Data from the Phase 3 SENTRY Trial in Myelofibrosis on Track for March 2026 – |
| 12 Jan 2026 |
8-K: Results of Operations and Financial Condition; Other Events
Karyopharm Announces Preliminary Unaudited 2025 Revenue and Reiterates Expectation of Delivering Potentially Transformative Phase 3 Data in 2026 |
| 03 Nov 2025 |
8-K: Results of Operations and Financial Condition
– Top-Line Data from the Phase 3 SENTRY Trial in Myelofibrosis on Track for March 2026 – |
Loading...